Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BACI-RX vs BACTROBAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.
Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.
FDA-approved: Treatment of superficial skin infections caused by susceptible organisms,Off-label: Ophthalmic infections (conjunctivitis, blepharitis), nasal carriage of Staphylococcus aureus
Impetigo due to Staphylococcus aureus and Streptococcus pyogenes,Mupirocin-sensitive infections
1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.
Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.
Terminal half-life: 2-3 hours in patients with normal renal function; prolonged to 20-40 hours in anuria. Clinical context: Dosing interval adjustment required for creatinine clearance <30 m L/min.
Terminal elimination half-life: 1-1.5 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in end-stage renal disease)
Bacitracin is not systemically absorbed after topical administration; no significant hepatic metabolism. Systemic absorption can occur with large topical doses or use on denuded skin, and it is excreted primarily unchanged by the kidneys.
Minimal systemic absorption; rapidly metabolized to monic acid (inactive) in skin and systemically.
Renal: 90-100% as unchanged drug via glomerular filtration; biliary/fecal: negligible.
Renal (90-95% unchanged), with minor biliary/fecal elimination (<5%)
Approximately 10-20% bound to serum proteins (albumin).
95% bound, primarily to albumin
0.25-0.4 L/kg. Low Vd indicates distribution primarily to extracellular fluid; minimal tissue penetration except renal cortex.
0.15-0.3 L/kg, indicating distribution primarily into extracellular fluid
Intramuscular: ~100% (rapid and complete); oral: negligible (<1%) due to poor absorption; topical: variable, minimal systemic absorption (<5% with intact skin).
Topical: Negligible systemic absorption (<0.05% after topical application to intact skin; slightly higher (up to 1%) on abraded skin; intranasal: <0.1%
No adjustment required; bacitracin is not significantly renally eliminated.
No dosage adjustment necessary for topical application. For intranasal use, no adjustment required. Systemic absorption is minimal.
No adjustment required; bacitracin is not hepatically metabolized.
No dosage adjustment necessary for topical or intranasal use. Systemic absorption is minimal.
Weight-based dosing as per standard protocol: 1-2 units/kg intramuscularly every 2-4 hours; adjust based on factor levels.
Children 3 months and older: Same as adult dosing. Topical: apply 2% ointment/cream three times daily for 5 to 14 days. Intranasal: apply 0.5 g of 2% ointment to each nostril twice daily for 5 days.
Use standard dosing with caution for renal function; assess GFR and adjust if impaired.
No specific adjustments required. Use same dosing as adults. Caution in patients with renal impairment due to potential accumulation of polyethylene glycol vehicle with extensive use on open wounds or burns.
No FDA black box warning.
None.
Nephrotoxicity with systemic absorption; avoid use on large surface areas or deep wounds; hypersensitivity reactions; potential for superinfection; not for ophthalmic use unless specifically formulated.
Severe allergic reactions including anaphylaxis and angioedema; potential for superinfection with prolonged use; not for intranasal use except specific formulations.
Hypersensitivity to bacitracin or any component of the formulation; severe renal impairment (if systemic absorption is possible).
Known hypersensitivity to mupirocin or any component of the formulation.
No known food interactions with topical bacitracin.
No known food interactions. The drug is applied topically; oral intake does not affect its action.
First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.
No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.
Unknown if excreted in human milk; M/P ratio not available. Caution is advised; consider temporary discontinuation of breastfeeding or drug based on importance to mother.
Unknown if excreted in human milk; caution advised. M/P ratio not established.
No dose adjustment required due to pregnancy-related pharmacokinetic changes; dose based on indication and renal function.
No dose adjustments recommended; systemic absorption is minimal.
BACI-RX (bacitracin) is a topical antibiotic effective against gram-positive organisms. Avoid systemic use due to nephrotoxicity. Apply thin layer; hypersensitivity reactions possible. Not for ophthalmic use unless specified. Monitor for superinfection with prolonged use.
BACTROBAN (mupirocin) is a topical antibiotic effective against methicillin-resistant Staphylococcus aureus (MRSA) and Streptococcus pyogenes. It is contraindicated for use on burns or large open wounds due to risk of polyethylene glycol absorption. For impetigo, apply to affected area three times daily for 5-10 days. Not effective against fungal, viral, or anaerobic infections. Monitor for local irritation; discontinue if severe. Use intranasal formulation (BACTROBAN Nasal) for MRSA decolonization.
Apply a thin layer to affected area as directed.,Wash hands before and after application unless treating hands.,Do not use on large areas of skin or deep puncture wounds.,Stop use and consult provider if rash or irritation develops.,Do not use in eyes or mouth unless specifically prescribed.,Store at room temperature away from moisture and heat.
Apply a small amount of ointment to the affected area 3 times daily, or as directed.,Wash hands before and after application to prevent spreading infection.,Do not use on large areas of broken skin or deep wounds without medical advice.,Avoid contact with eyes and mucous membranes.,Complete the full course of treatment even if symptoms improve.,Stop use and contact doctor if rash or irritation occurs.,Do not share this medication with others.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BACI-RX vs BACTROBAN, answered by our medical review team.
BACI-RX is a Topical Antibiotic that works by Bacitracin inhibits bacterial cell wall synthesis by interfering with the dephosphorylation of the lipid carrier that transports peptidoglycan precursors, thereby blocking cell wall formation.. BACTROBAN is a Topical Antibiotic that works by Binds to isoleucyl-t RNA synthetase, inhibiting bacterial protein synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BACI-RX and BACTROBAN depend on the specific clinical indication. These are both Topical Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BACI-RX is: 1-2 units/kg intramuscularly every 2-4 hours as needed for hemophilia A; intravenous infusion 40-50 units/kg for major surgery or life-threatening bleeding, then 20-25 units/kg every 8 hours.. The standard adult dose of BACTROBAN is: Mupirocin (Bactroban) 2% ointment or cream applied topically to affected area three times daily for 5 to 14 days. For intranasal use: 0.5 g of 2% ointment applied to each nostril twice daily for 5 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BACI-RX and BACTROBAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BACI-RX is classified as Category C. First trimester: No evidence of teratogenicity in animal studies; limited human data. Second and third trimesters: No known fetal risks; use only if clearly needed.. BACTROBAN is classified as Category C. No evidence of teratogenicity in animal studies; limited human data; FDA Pregnancy Category B. Use only if clearly needed.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.